ST. LOUIS, June 14, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and Saint Alphonsus Health System in Idaho today announced that Dr. Margot Vloka has completed more than 500 cardiac ablation procedures using the Niobe® ES remote magnetic navigation system. Dr. Vloka is a board-certified clinical cardiac electrophysiologist (EP) at the Saint Alphonsus Stereotaxis lab and a Fellow of the Heart Rhythm Society.
The Niobe ES system was introduced in the U.S. at the end of 2011 and installed the following year at Saint Alphonsus Health System, making it the first provider in Idaho to utilize remote magnetic navigation for ablation procedures. Having experience with the Niobe system while at the Wisconsin Heart Hospital, Dr. Vloka was a vocal proponent of the technology when arriving at Saint Alphonsus in late 2014. After training on the latest generation Niobe ES system with the aid of the Company’s best practices program, Dr. Vloka quickly adopted the Niobe ES system as part of her daily clinical routine for the treatment of atrial arrhythmias, ventricular tachycardia, congenital heart disease and other complex cardiac conditions.
“I have always been a ‘belt and suspenders’ type physician, especially given the delicacy of the cardiovascular system, and with the Niobe system, I have complete peace of mind that I am providing the safest approach to cardiac ablation,” said Dr. Vloka. “The Niobe system’s remote, computer-assisted features reduce risk of complications and enable me to create more effective lesions with shorter procedure times than traditional manual and mechanical therapies. As a result, I am able to complete multiple complex procedures each day and, most importantly, my patients are able to resume normal activities with freedom from debilitating arrhythmias.”
Tom Reinhardt, Assistant Vice President for Saint Alphonsus Health System, said “We are very pleased to be the only healthcare provider in the state to offer this groundbreaking treatment for cardiac ablations. The level of expertise Dr. Vloka has achieved with Stereotaxis technologies continues to raise the bar for EP professionals in the region. The Niobe system and its suite of automations has been a strong addition to the Saint Alphonsus cardiology services line, expanding our capabilities to better serve patients across the region.”
About Saint Alphonsus Health System
As a faith-based Catholic ministry and not-for-profit health system, Saint Alphonsus Health System reinvests in the communities we serve, through charity care and other benefits. Our goal is to improve the health and well-being of people by emphasizing care that is patient-centered, physician-led, innovative and community-based. Saint Alphonsus Health System serves the people of southwestern Idaho, eastern Oregon and northern Nevada through these facilities: Saint Alphonsus Regional Medical Center - Boise, ID; Saint Alphonsus Medical Center - Nampa, ID; Saint Alphonsus Medical Center - Ontario, OR; Saint Alphonsus Medical Center - Baker City, OR; and, Saint Alphonsus Medical Group with primary and specialty care providers at over 60 clinic locations, all of which are members of the Saint Alphonsus Health Alliance, a network of over 1900 employed and independent providers. Saint Alphonsus is a proud affiliate of Trinity Health, one of the largest multi-institutional Catholic health care delivery systems in the nation. Trinity Health serves people and communities in 21 states from coast to coast with 88 hospitals and 126 continuing care facilities, home health and hospice programs, and PACE center locations that provide more than 2.5 million visits annually. To find out more go to: www.saintalphonsus.org.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its continued listing on the NASDAQ Capital Market, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
Company Contact: Martin C. Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 firstname.lastname@example.org